Cigna Eyes Biosimilars Competing With 25% Of ‘Specialty’ Products
US Insurer Lauds ‘Societal Opportunity,’ Comments On Potential Margin Profile
Ahead of adding Humira (adalimumab) biosimilars to its national preferred formulary from 1 February, Cigna spoke about the potential and opportunity of biosimilar competition in the US, which lags behind other OECD member countries.
You may also be interested in...
Teva has wrapped up an earlier deal with Sanofi that will see the French giant take command of its novel TL1A inhibitor currently in a Phase IIb study for ulcerative colitis and Crohn’s disease.
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.